XJPX7096
Market cap94mUSD
Jan 23, Last price
1,445.00JPY
1D
0.77%
1Q
-17.52%
IPO
-26.28%
Name
StemCell Institute
Chart & Performance
P/E
47.61
P/S
5.97
EPS
30.35
Div Yield, %
1.73%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2.48b
+18.64%
Net income
311m
+57.04%
CFO
335m
+235.73%
Dividend
Sep 27, 202425 JPY/sh
Profile
StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 2,481,193 18.64% | 2,091,293 17.36% | 1,781,943 26.42% | ||
Cost of revenue | 2,059,735 | 1,790,450 | 1,554,686 | ||
Unusual Expense (Income) | |||||
NOPBT | 421,458 | 300,843 | 227,257 | ||
NOPBT Margin | 16.99% | 14.39% | 12.75% | ||
Operating Taxes | 130,346 | 80,924 | 78,827 | ||
Tax Rate | 30.93% | 26.90% | 34.69% | ||
NOPAT | 291,112 | 219,919 | 148,430 | ||
Net income | 310,981 57.04% | 198,032 48.09% | 133,726 114.40% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (91) | 644,373 | |||
BB yield | 0.00% | -3.17% | |||
| Debt | |||||
Debt current | 2,108 | 1,333 | |||
Long-term debt | 15,460 | 10,443 | |||
Deferred revenue | (13,599) | ||||
Other long-term liabilities | 85,324 | 76,900 | 45,176 | ||
Net debt | (3,479,339) | (3,695,347) | (3,751,693) | ||
| Cash flow | |||||
Cash from operating activities | 334,625 | 99,672 | 469,290 | ||
CAPEX | (183,000) | (59,903) | (204,481) | ||
Cash from investing activities | (811,773) | (285,100) | 404,170 | ||
Cash from financing activities | (1,333) | (869) | 644,373 | ||
FCF | 274,012 | 219,467 | 77,417 | ||
| Balance | |||||
Cash | 2,845,540 | 3,324,021 | 3,511,319 | ||
Long term investments | 651,367 | 383,102 | 240,374 | ||
Excess cash | 3,372,847 | 3,602,558 | 3,662,596 | ||
Stockholders' equity | 2,023,191 | 1,712,210 | 1,515,177 | ||
Invested Capital | 761,970 | 593,121 | 556,078 | ||
ROIC | 42.97% | 38.27% | 34.47% | ||
ROCE | 15.13% | 12.97% | 10.89% | ||
| EV | |||||
Common stock shares outstanding | 10,247 | 10,247 | 10,129 | ||
Price | 1,986.00 -21.03% | 2,515.00 25.28% | 2,007.50 | ||
Market cap | 20,349,656 -21.03% | 25,770,093 26.74% | 20,333,321 | ||
EV | 16,870,317 | 22,076,746 | 16,581,628 | ||
EBITDA | 542,052 | 405,775 | 324,170 | ||
EV/EBITDA | 31.12 | 54.41 | 51.15 | ||
Interest | 27 | ||||
Interest/NOPBT | 0.01% | ||||